Overview Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen) Status: Recruiting Trial end date: 2022-09-01 Target enrollment: Participant gender: Summary Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): an open-label, single-center, phase 2, single-arm trial (CaboPen) Phase: Phase 2 Details Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano